# Harmony Biosciences Shares First Phase 1 Clinical Data for Orexin-2 Agonist BP-205 Showing Favorable Safety Profile

> clinical trial · REPORTED · 2026-08-04

Alongside its Q2 earnings on August 4, 2026, Harmony Biosciences released initial Phase 1 single-ascending-dose data for BP-205, its orexin-2 receptor agonist pipeline candidate, demonstrating favorable pharmacokinetics and a clean safety and tolerability profile that the company described as reinforcing its potential best-in-class profile. The data represent the first human clinical readout for BP-205.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a pharmaceutical company dedicated to rare neurological diseases, commercially anchored by WAKIX (pitolisant) for narcolepsy and building a pipeline of novel CNS therapies targeting the histamine H3 and orexin receptor systems.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://natlawreview.com/press-releases/harmony-biosciences-announces-record-q2-2026-revenue-and-shares-initial

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.